BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ALN-CIDEB readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ALN-CIDEB\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06836609-6930@assetmemo.bio
DTSTAMP:20261121T005436Z
DTSTART;VALUE=DATE:20270817
DTEND;VALUE=DATE:20270818
SUMMARY:ALN-CIDEB: Phase 1/2 readout est. (NCT06836609)
DESCRIPTION:ALN-CIDEB\, phase 1/2\, MASH / NASH.\nStudy: A Study to Evaluat
 e ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated St
 eatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepat
 itis (MASLD/MASH)\nEstimated primary completion: 17 August 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/aln-cideb#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06836609
URL:https://assetmemo.bio/drug/aln-cideb#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07631637-6930@assetmemo.bio
DTSTAMP:20261121T005436Z
DTSTART;VALUE=DATE:20290129
DTEND;VALUE=DATE:20290130
SUMMARY:ALN-CIDEB: Phase 2 readout est. (NCT07631637)
DESCRIPTION:ALN-CIDEB\, phase 2\, MASH / NASH.\nStudy: Study to Evaluate AL
 N-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohep
 atitis (MASH)\nEstimated primary completion: 29 January 2029. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/aln-cideb#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07631637
URL:https://assetmemo.bio/drug/aln-cideb#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07854782-6930@assetmemo.bio
DTSTAMP:20261121T005436Z
DTSTART;VALUE=DATE:20290303
DTEND;VALUE=DATE:20290304
SUMMARY:ALN-CIDEB: Phase 3 readout est. (NCT07854782)
DESCRIPTION:ALN-CIDEB\, phase 3\, MASH / NASH.\nStudy: Trial to Evaluate AL
 N-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Di
 sease (MASLD)\nEstimated primary completion: 3 March 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/aln-cideb#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07854782
URL:https://assetmemo.bio/drug/aln-cideb#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07933328-6930@assetmemo.bio
DTSTAMP:20261121T005436Z
DTSTART;VALUE=DATE:20290507
DTEND;VALUE=DATE:20290508
SUMMARY:ALN-CIDEB: Phase 2 readout est. (NCT07933328)
DESCRIPTION:ALN-CIDEB\, phase 2.\nStudy: Study to Evaluate ALN-CIDEB in Adu
 lts With Fibrotic Alcohol-Associated Liver Disease (ALD)\nEstimated primar
 y completion: 7 May 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/aln-cideb#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07933328
URL:https://assetmemo.bio/drug/aln-cideb#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
